Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Posit...( DETROIT July 28 /- Caraco Pharm...),Health

DETROIT, July 28 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that Jitendra N. Doshi has been appointed as interim Chief Executive Officer and as a Director of the Company following the resignation of Daniel H. Movens as Chief Executive Officer and as a Director effective at the close of business today. During Mr. Movens' tenure, Caraco experienced substantial product expansion and revenue growth. Mr. Movens will assist the Company as a resource during the transition. Mr. Doshi has previously served as Caraco's interim Chief Executive Officer (from September 2003 to May 2005). He has also served Caraco in other executive capacities since April 2001. Prior to his appointment, from 2006 to July 2009, Mr. Doshi was the Executive Director of Sun Pharmaceutical Industries, Inc., a wholly-owned subsidiary of Sun Pharma.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: informati
'/>"/>